Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD

Jørgen Vestbo; Claus Vogelmeier; Jacques Creemers; Meritxell Falques; Anna Ribera; Esther Garcia Gil

doi:10.3109/15412555.2010.510158

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD

Jørgen Vestbo, Claus Vogelmeier, Jacques Creemers, Meritxell Falques, Anna Ribera, Esther Garcia Gil

Research output: Contribution to journal › Article › peer-review

Abstract

Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium. This was a double-blind, double-dummy, multicenter, crossover study in COPD patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and

Original language	English
Pages (from-to)	331-336
Number of pages	5
Journal	COPD: Journal of Chronic Obstructive Pulmonary Disease
Volume	7
Issue number	5
DOIs	https://doi.org/10.3109/15412555.2010.510158
Publication status	Published - Sept 2010

Keywords

Aclidinium bromide
Bronchodilation
Chronic obstructive pulmonary disease
Muscarinic antagonist
Onset of action

Access to Document

10.3109/15412555.2010.510158

Cite this

@article{226a8a84b6304426b637695f84ac89c5,

title = "Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD",

abstract = "Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium. This was a double-blind, double-dummy, multicenter, crossover study in COPD patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and",

keywords = "Aclidinium bromide, Bronchodilation, Chronic obstructive pulmonary disease, Muscarinic antagonist, Onset of action",

author = "J{\o}rgen Vestbo and Claus Vogelmeier and Jacques Creemers and Meritxell Falques and Anna Ribera and Gil, {Esther Garcia}",

year = "2010",

month = sep,

doi = "10.3109/15412555.2010.510158",

language = "English",

volume = "7",

pages = "331--336",

journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",

issn = "1541-2555",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD

AU - Vestbo, Jørgen

AU - Vogelmeier, Claus

AU - Creemers, Jacques

AU - Falques, Meritxell

AU - Ribera, Anna

AU - Gil, Esther Garcia

PY - 2010/9

Y1 - 2010/9

N2 - Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium. This was a double-blind, double-dummy, multicenter, crossover study in COPD patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and

AB - Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium. This was a double-blind, double-dummy, multicenter, crossover study in COPD patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and

KW - Aclidinium bromide

KW - Bronchodilation

KW - Chronic obstructive pulmonary disease

KW - Muscarinic antagonist

KW - Onset of action

U2 - 10.3109/15412555.2010.510158

DO - 10.3109/15412555.2010.510158

M3 - Article

C2 - 20854047

SN - 1541-2555

VL - 7

SP - 331

EP - 336

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

IS - 5

ER -

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD

Abstract

Keywords

Access to Document

Fingerprint

Cite this